165 related articles for article (PubMed ID: 38498620)
1. Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
Wyse JJ; Eckhardt A; Waller D; Gordon AJ; Shull S; Lovejoy TI; Mackey K; Morasco BJ
J Addict Med; 2024 May-Jun 01; 18(3):300-305. PubMed ID: 38498620
[TBL] [Abstract][Full Text] [Related]
2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
3. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
4. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
5. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
Samples H; Williams AR; Olfson M; Crystal S
J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
[TBL] [Abstract][Full Text] [Related]
6. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
7. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
[TBL] [Abstract][Full Text] [Related]
8. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
[TBL] [Abstract][Full Text] [Related]
9. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
11. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
[TBL] [Abstract][Full Text] [Related]
12. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
Samples H; Williams AR; Crystal S; Olfson M
J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
[TBL] [Abstract][Full Text] [Related]
14. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
Couch JV; Whitcomb M; Buchheit BM; Dorr DA; Malinoski DJ; Korthuis PT; Ono SS; Levander XA
Harm Reduct J; 2024 Jun; 21(1):125. PubMed ID: 38937779
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
16. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
17. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
18. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
19. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
20. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
